YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer

Masafumi Horie1,2, Akira Saito1,2, Mitsuhiro Ohshima3

  • 1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Cancer Science
|September 15, 2016
PubMed

Insights

Small cell lung cancer (SCLC) subtypes exist. A novel YAP/TAZ subgroup shows distinct cell morphology, gene expression, and drug sensitivity, offering new therapeutic avenues for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Small cell lung cancer (SCLC) is aggressive, metastatic, and develops chemoresistance.
  • Genomic and transcriptome studies reveal SCLC heterogeneity.
  • Subtyping SCLC may improve therapeutic response prediction and prognosis.

Purpose of the Study:

  • To classify SCLC based on transcriptional networks.
  • To identify and characterize a novel SCLC subgroup.
  • To investigate the role of YAP/TAZ in SCLC biology and drug sensitivity.

Main Methods:

  • Transcriptome data analysis of SCLC cell lines.
  • Transcriptional network-defined classification.
  • YAP knockdown experiments and microarray analysis.
  • Assessment of cell morphology and drug sensitivity.

Main Results:

  • A distinct SCLC subgroup with high YAP/TAZ expression was identified.
  • This YAP/TAZ subgroup exhibits specific cell morphology, gene expression profiles (lower ASCL1, higher laminin/integrin), and drug sensitivities.
  • YAP knockdown induced morphological changes, and YAP regulates genes like AJUBA, which also impacts cell morphology.

Conclusions:

  • A novel YAP/TAZ-expressing SCLC subtype has been identified.
  • This subtype presents unique molecular characteristics and clinical implications for drug sensitivity.
  • Understanding these molecular networks is crucial for addressing SCLC heterogeneity and improving treatment outcomes.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K